U.S. flag

An official website of the United States government

Display Settings:

Format
Sort by

Send to:

Choose Destination

Links from dbGaP

Items: 5

1.
Pharmacogenetics of Efavirenz Discontinuation for Reported Central Nervous System Symptoms Appears to Differ by Race
Paul Leger, Sanika Chirwa, Megan Turner, Danielle M. Richardson, Paxton Baker, Michael Leonard, Husamettin Erdem, Lana Olson, David W. Haas
Pharmacogenet Genomics. Author manuscript; available in PMC 2017 Oct 1.
Published in final edited form as: Pharmacogenet Genomics. 2016 Oct; 26(10): 473–480. doi: 10.1097/FPC.0000000000000238
PMCID:
PMC5014672
AbstractArticlePDF–897K
2.
Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes
David W. Haas, Awewura Kwara, Danielle M. Richardson, Paxton Baker, Ioannis Papageorgiou, Edward P. Acosta, Gene D. Morse, Michael H. Court
J Antimicrob Chemother. 2014 Aug; 69(8): 2175–2182. Published online 2014 Apr 11. doi: 10.1093/jac/dku110
PMCID:
PMC4100708
AbstractArticlePDF–362K
3.
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Emily R. Holzinger, Benjamin Grady, Marylyn D. Ritchie, Heather J. Ribaudo, Edward P. Acosta, Gene D. Morse, Roy M. Gulick, Gregory K. Robbins, David B. Clifford, Eric S. Daar, Paul McLaren, David W. Haas
Pharmacogenet Genomics. Author manuscript; available in PMC 2013 Dec 1.
Published in final edited form as: Pharmacogenet Genomics. 2012 Dec; 22(12): 858–867. doi: 10.1097/FPC.0b013e32835a450b
PMCID:
PMC3614365
AbstractArticlePDF–2.3M
4.
Association of Pharmacogenetic Markers with Premature Discontinuation of First-line Anti-HIV Therapy: An Observational Cohort Study
Rubin Lubomirov, Sara Colombo, Julia di Iulio, Bruno Ledergerber, Raquel Martinez, Matthias Cavassini, Bernard Hirschel, Enos Bernasconi, Luigia Elzi, Pietro Vernazza, Hansjakob Furrer, Huldrych F. Günthard, Amalio Telenti, the Swiss HIV Cohort Study
J Infect Dis. 2011 Jan 15; 203(2): 246–257. doi: 10.1093/infdis/jiq043
PMCID:
PMC3071070
AbstractArticlePDF–260K
5.
Impact of CYP2B6, ABCB1 and CYP3A5 Polymorphisms on Efavirenz Pharmacokinetics and Treatment Response: An AIDS Clinical Trials Group Study
Heather J. Ribaudo, Huan Liu, Matthias Schwab, Elke Schaeffeler, Michel Eichelbaum, Alison A. Motsinger-Reif, Marylyn D. Ritchie, Ulrich M Zanger, Edward P. Acosta, Gene D. Morse, Roy M. Gulick, Gregory K. Robbins, David Clifford, David W. Haas
J Infect Dis. Author manuscript; available in PMC 2011 Sep 1.
Published in final edited form as: J Infect Dis. 2010 Sep 1; 202(5): 717–722. doi: 10.1086/655470
PMCID:
PMC2919241
AbstractArticlePDF–2.2M

Display Settings:

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
You are here: NCBI > Literature > PubMed Central (PMC)
Support Center